Switch theme
Sign up to access all valuation multiples
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
2009
n/a
LTM Revenue $91.3M
LTM EBITDA -$1.8M
$3.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zelgen Biopharmaceuticals has a last 12-month revenue (LTM) of $91.3M and a last 12-month EBITDA of -$1.8M.
In the most recent fiscal year, Zelgen Biopharmaceuticals achieved revenue of $74.0M and an EBITDA of -$9.8M.
Zelgen Biopharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zelgen Biopharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $91.3M | XXX | $74.0M | XXX | XXX | XXX |
| Gross Profit | $84.2M | XXX | $68.8M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | -$1.8M | XXX | -$9.8M | XXX | XXX | XXX |
| EBITDA Margin | -2% | XXX | -13% | XXX | XXX | XXX |
| EBIT | -$14.3M | XXX | -$26.0M | XXX | XXX | XXX |
| EBIT Margin | -16% | XXX | -35% | XXX | XXX | XXX |
| Net Profit | -$13.4M | XXX | -$19.1M | XXX | XXX | XXX |
| Net Margin | -15% | XXX | -26% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Zelgen Biopharmaceuticals's stock price is CNY 109 (or $15).
Zelgen Biopharmaceuticals has current market cap of CNY 28.8B (or $4.0B), and EV of CNY 27.7B (or $3.8B).
See Zelgen Biopharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.8B | $4.0B | XXX | XXX | XXX | XXX | $-0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Zelgen Biopharmaceuticals has market cap of $4.0B and EV of $3.8B.
Zelgen Biopharmaceuticals's trades at 51.9x EV/Revenue multiple, and -392.0x EV/EBITDA.
Equity research analysts estimate Zelgen Biopharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zelgen Biopharmaceuticals has a P/E ratio of -297.7x.
See valuation multiples for Zelgen Biopharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.0B | XXX | $4.0B | XXX | XXX | XXX |
| EV (current) | $3.8B | XXX | $3.8B | XXX | XXX | XXX |
| EV/Revenue | 42.0x | XXX | 51.9x | XXX | XXX | XXX |
| EV/EBITDA | -2107.8x | XXX | -392.0x | XXX | XXX | XXX |
| EV/EBIT | -267.6x | XXX | -147.6x | XXX | XXX | XXX |
| EV/Gross Profit | 45.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -297.7x | XXX | -208.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -481.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialZelgen Biopharmaceuticals's last 12 month revenue growth is 68%
Zelgen Biopharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Zelgen Biopharmaceuticals's rule of 40 is 10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zelgen Biopharmaceuticals's rule of X is 167% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Zelgen Biopharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 68% | XXX | 67% | XXX | XXX | XXX |
| EBITDA Margin | -2% | XXX | -13% | XXX | XXX | XXX |
| EBITDA Growth | -1124% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 10% | XXX | 54% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 167% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 73% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 128% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zelgen Biopharmaceuticals acquired XXX companies to date.
Last acquisition by Zelgen Biopharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Zelgen Biopharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Zelgen Biopharmaceuticals founded? | Zelgen Biopharmaceuticals was founded in 2009. |
| Where is Zelgen Biopharmaceuticals headquartered? | Zelgen Biopharmaceuticals is headquartered in China. |
| Is Zelgen Biopharmaceuticals publicy listed? | Yes, Zelgen Biopharmaceuticals is a public company listed on SHG. |
| What is the stock symbol of Zelgen Biopharmaceuticals? | Zelgen Biopharmaceuticals trades under 688266 ticker. |
| When did Zelgen Biopharmaceuticals go public? | Zelgen Biopharmaceuticals went public in 2020. |
| Who are competitors of Zelgen Biopharmaceuticals? | Similar companies to Zelgen Biopharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Zelgen Biopharmaceuticals? | Zelgen Biopharmaceuticals's current market cap is $4.0B |
| What is the current revenue of Zelgen Biopharmaceuticals? | Zelgen Biopharmaceuticals's last 12 months revenue is $91.3M. |
| What is the current revenue growth of Zelgen Biopharmaceuticals? | Zelgen Biopharmaceuticals revenue growth (NTM/LTM) is 68%. |
| What is the current EV/Revenue multiple of Zelgen Biopharmaceuticals? | Current revenue multiple of Zelgen Biopharmaceuticals is 42.0x. |
| Is Zelgen Biopharmaceuticals profitable? | Yes, Zelgen Biopharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zelgen Biopharmaceuticals? | Zelgen Biopharmaceuticals's last 12 months EBITDA is -$1.8M. |
| What is Zelgen Biopharmaceuticals's EBITDA margin? | Zelgen Biopharmaceuticals's last 12 months EBITDA margin is -2%. |
| What is the current EV/EBITDA multiple of Zelgen Biopharmaceuticals? | Current EBITDA multiple of Zelgen Biopharmaceuticals is -2107.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
